secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001140361-24-026107
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech Q1 net loss $10.6M; VERSATILE-002 shows median OS of 30 months in HNSCC
--------------------------------------------------------------------------------

- VERSATILE-002 Phase 2: median overall survival 30 months (vs 7-18 months for ICIs); BOR 34% (CPS≥1), 48% (CPS≥20).
- Updated registrational trial strategy: triple combination Versamune HPV + PDS01ADC + pembrolizumab in first-line HNSCC.
- Appointed Stephan Toutain as COO; brings commercial experience.
- Two patents granted by Israel and Australia extending Versamune platform protection through 2036-2038.
- Q1 net loss $10.6M ($0.30/share); cash $66.6M; R&D expenses $6.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036124026107/0001140361-24-026107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036124026107/ef20029143_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-026107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer